From the University of Illinois Chicago College of Medicine.
Division of Dermatology, Department of Medicine, University of Arizona, Tucson.
Dermatitis. 2021;32(1):15-18. doi: 10.1097/DER.0000000000000616.
Clinical trials are currently underway to evaluate the benefit of dupilumab in treating allergic contact dermatitis (ACD). Dupilumab use has been reported to improve ACD reactions in some patients, but not all. Varying clinical responses to T helper 2 (TH2) inhibition challenge the classical view that ACD proceeds through a TH1-dominant pathway. Selective TH2 inhibitors, such as dupilumab, may attenuate ACD when the delayed hypersensitivity response is due to TH2-predominate activation; conversely, it may have no effect on ACD if it is elicited via TH1 or TH17 pathways. We hypothesize that allergen-specific T-cell responses and patient-specific factors both play an important role in determining which pathways are recalled in delayed hypersensitivity reactions.
目前正在进行临床试验，以评估度普利尤单抗治疗过敏性接触性皮炎（ACD）的疗效。据报道，度普利尤单抗的使用可以改善某些患者的 ACD 反应，但并非所有患者都如此。针对 T 辅助 2（TH2）抑制的不同临床反应挑战了 ACD 通过 TH1 优势途径进展的经典观点。选择性 TH2 抑制剂，如度普利尤单抗，在迟发性超敏反应是由于 TH2 优势激活时，可能会减轻 ACD；相反，如果它是通过 TH1 或 TH17 途径引发的，则可能对 ACD 没有影响。我们假设过敏原特异性 T 细胞反应和患者特异性因素都在决定迟发性超敏反应中激活哪些途径方面发挥重要作用。
